about
Diagnosis and management of the metabolic syndrome in obesityDoes combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Sibutramine-associated adverse effects: a practical guide for its safe use.Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals.Combination drug treatment in obese diabetic patientsDyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentIs the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?Sibutramine on cardiovascular outcome.Peripheral endocannabinoid system activity in patients treated with sibutramine.Present and future therapeutic strategies in non-alcoholic fatty liver disease.Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management.The use of sibutramine in the management of obesity and related disorders: an update.Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis.The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions.Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study.Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus.The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome.Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds.New options for drug treatment of obesity in patients with Type 2 diabetes.The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea.
P2860
Q28192856-12435A57-FFA4-4D44-BBE0-8E96311ED3C9Q33776187-21E66257-4432-496D-A104-A0AD5F1F42BCQ34585304-7CBD9E6D-5CFC-4D7E-8C8D-26DD669B08CCQ34591803-FFB8F7FD-A969-4BE1-A475-E1FFD5532A66Q34637721-9FCA96C9-9EE7-415D-9769-70BAC246EC6FQ34877652-18F1111A-E2BE-4223-B56C-CBFBDFB74CB9Q35029623-F6CB6A88-7DE6-4044-8E3A-EAD50EB12F36Q36273465-2BCAA839-8EF5-4417-8D45-65C92C7994E0Q36783695-4C6ED5DF-9EB8-4285-A630-C484A25B18EDQ36857391-3F8F4BFE-4BEF-4EFA-9B90-6706BD23DE85Q36936358-6952BC4A-C261-4580-8DF0-1E6EE1B43D24Q37039725-736ECF5E-949E-441D-87CC-7FB57E8A1C8AQ37202159-29DFB6DD-65CF-4019-B191-7F47A4B2AD22Q37402140-2B0F46A6-625A-4B9F-8AEA-0571AB638909Q37410873-488F93D9-3506-47BC-9521-18E44F9D3A24Q37494318-C0119376-B8F2-422B-A40A-BAA3E7476914Q37708767-DC4A44A9-A1AF-4A8F-B5BB-61E7C7ACC588Q37831334-DF946563-DDBB-4819-809A-B5CB74E1B590Q37831911-8F167FFF-7084-430C-8701-2DFB9FA2945AQ38047387-F772E7AC-2B34-47D2-AD32-BBCA0EC3C6BAQ39699152-E1C067AA-9B4C-4905-8D46-479BD272B60EQ46657507-3D197C01-6FBC-49CA-A6B5-9CCFFBC676E6Q47339304-BCF6C7F7-94F8-44B3-906A-5C6171489375
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A review of the metabolic effects of sibutramine.
@ast
A review of the metabolic effects of sibutramine.
@en
type
label
A review of the metabolic effects of sibutramine.
@ast
A review of the metabolic effects of sibutramine.
@en
prefLabel
A review of the metabolic effects of sibutramine.
@ast
A review of the metabolic effects of sibutramine.
@en
P50
P356
P1476
A review of the metabolic effects of sibutramine
@en
P2093
Kiortsis DN
Mikhailidis DP
P304
P356
10.1185/030079905X38132
P407
P577
2005-03-01T00:00:00Z